Cytek Biosciences (US.CTKB)
资本配置审计 · 期间： 2019 – 2026
核心指标
US.CTKB · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 424.7% | ↓ |
| ROE | -9.6% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.08 | ↓ |
| Gross Margin | 53.7% | ↑ |
US.CTKB (Cytek Biosciences) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 424.7% ↓ ROE -9.6% ↓ Cash Conversion - → D/E Ratio 0.08 ↓ Gross Margin 53.7% ↑
核心指标
US.CTKB (Cytek Biosciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 424.7% ↓ROE -9.6% ↓Cash Conversion - →D/E Ratio 0.08 ↓Gross Margin 53.7% ↑免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies